Sumaira Ahmed

3 weeks ago | neurologylive.com | Sumaira Ahmed |Isabella Ciccone

WATCH TIME: 2 minutes"We are super hopeful and excited about all that we will learn, especially what it will mean for patients, about the different therapies available to [those with NMOSD] and which ones may be best suited for them."Despite the influx of recently approved therapies for patients with neuromyelitis optica spectrum disorder (NMOSD), patients still opt to use off-label treatments like rituximab to suppress disease activity.